[2021] Ischemia Reperfusion Injury Therapeutics Market Size to Expand at Highest Revenue US$ 2,290.1 Million with Growth Rate at 5.4% CAGR by 2027

SEATTLE, April 29, 2021, (PHARMIWEB) — Global Ischemia Reperfusion Injury Therapeutics Market

Overview:

Ischemic reperfusion injury, also known as reoxygenation injury, occurs when the blood supply to an area of tissue is cut off. The number of patients with ischemia reperfusion injury is increasing rapidly with the increasing burden of cardiovascular diseases (CVDs) worldwide. This is a critical medical condition that is a major medical challenge for physicians. The symptoms of ischemia injury include seizures, hypertension, headache, and bradycardia.

The ischemia-reperfusion injury therapeutics market is valued at US$ 1,582.33 million in 2020 and is expected to rise at a CAGR of 5.4% during the forecast period (2020-2027).

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/4105

COVID-19 Impact:

The outbreak of COVID-19 has adversely affected the growth of the global ischemia reperfusion therapies market as it has become difficult to conduct research in the current situation. Thus, key players operating in the market are adopting various inorganic strategies to help individuals with ischemic reperfusion injury during the current crisis. Moreover, several governments worldwide are implementing various regulations to deal with the pandemic.

Drivers:

Increase in product launches and approvals and increase in the number of mergers and acquisitions are expected to augment the global ischemia reperfusion injury therapeutics market growth over the forecast period. For instance, in November 2019, Faraday Pharmaceuticals announced top-line results from its Phase II trial of FDY-5301 for the treatment of reperfusion injury following ST elevation myocardial infarction. Moreover, in January 2020, Revive Therapeutics provided an update on the Company’s clinical development plan for Cannabidiol (CBD) in the treatment of Autoimmune Hepatitis (AIH).

Furthermore, increase in research and development for novel treatment and increasing awareness among people about ischemia reperfusion injury is expected to drive the market growth.

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4105

Restraints:     

High cost and the risk involved in the treatment is expected to hinder growth of the global ischemia reperfusion injury therapeutics market.

Market Taxonomy:

By Indication:

• Intestine Injury,
• Heart Injury,
• Kidney Injury,
• Other Injury.

By Distribution Channel:

• Hospital Pharmacies,
• Retail Pharmacies,

By Region:    

• Asia Pacific
• Latin America
• North America
• Africa
• Europe
• Middle East

Regional Analysis:

North America is expected to witness significant growth in the global ischemia reperfusion therapeutics market due to increase in research and development and increasing product approvals. For instance, in 2019, Abiomed announced that the U.S. Food and Drug Administration (FDA) approved initiation of the ST-Elevation Myocardial Infarction Door-to-Unloading (STEMI DTU) Pivotal Randomized Controlled Trial.

Moreover, Asia Pacific is also expected to witness robust growth in the global ischemia reperfusion therapeutics market due to increase in research and development and collaborative agreements between market players.

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/ischemia-reperfusion-injury-therapeutics-market-3364

Competitive Section:

Major players active in the global ischemia reperfusion injury therapeutics market are Bayer AG, Curatis Pharma GmbH, Nyken B.V., Orexo AB, Proteo, Inc., Prothix BV, Stealth BioTherapeutics Inc., Bolder Biotechnology, Inc., Prolong Pharmaceuticals, Ensemble Therapeutics Corporation, PledPharma AB, Pharming Group N.V., Omeros Corporation, Amyndas Pharmaceuticals LLC, Biomedica Management Corporation, Erimos Pharmaceuticals, Antipodean Pharmaceuticals, Inc., Opsona Therapeutics, Zealand Pharma A/S, Angion Biomedica Corp., and Gilead Sciences, Inc.

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837